Tracer library / [111In]3p-C-NETA-ePSMA-16

[111In]3p-C-NETA-ePSMA-16

Also written as [In-111]In-3p-C-NETA-ePSMA-16

Radionuclide: In-111 t½ 4031.6 min
Modality: Therapy
Production route: —
Stage: Preclinical
Syntheses indexed: 1

Prostate cancer

What it is

Compound class: PSMA-targeting NETA-based bifunctional chelator conjugate (PSMA-targeting radiotheranostic agent)
Target / mechanism: PSMA (prostate-specific membrane antigen) PMID 37375829
Clinical application: Imaging and treatment of prostate cancer PMID 37375829
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	—	99.7 ± 0.2%	>99%	3p-C-NETA-ePSMA-16	37375829 2023 Pharmaceuticals (Basel) Radiolabeling with 111In afforded quantitative radiochemical yield (RCY) (99.7 ± 0.2%, n = 5) in mild conditions (rt, 5 min) - Radiolabeling with 111In afforded quantitative radiochemical yield (RCY) (99.7 ± 0.2%, n = 5)

Need this precursor?We can point you to suppliers for [111In]3p-C-NETA-ePSMA-16, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 37375829. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 37375829: '3p-C-NETA-ePSMA-16 (1 nmol) dissolved in H2O was added to the solution'. Stage set/updated at stage 39 from PMID 37375829: 'Specific tumor uptake of [111In]In-3p-C-NETA-ePSMA-16 was observed up to 4 h p.i. (1.62 ± 0.55% ID/g at 1 h p.i.; 0.89 ± 0.58% ID/g at 4 h p.i.) in LS174T tumor-bearing mice.'.